Premium
Peripheral neutrophil inclusions in amiodarone treated patients.
Author(s) -
Adams PC,
Sloan P,
Morley AR,
Holt DW
Publication year - 1986
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1986.tb02968.x
Subject(s) - amiodarone , medicine , metabolite , peripheral blood , drug , toxicity , peripheral , plasma levels , pharmacology , active metabolite , gastroenterology , atrial fibrillation
In 14 patients receiving chronic amiodarone therapy the appearance of multilamellar inclusion bodies in peripheral blood neutrophils was related to both plasma concentrations of amiodarone and its desethyl metabolite and unwanted effects of the drug. Seven of the patients had well defined inclusion bodies. In this group mean amiodarone and desethylamiodarone concentrations were significantly higher than in the remaining seven patients and all but one had unwanted effects of the drug. Of the seven patients without inclusion bodies only one, with high plasma amiodarone and desethylamiodarone concentrations, had unwanted effects of the drug. It is concluded that the appearance of multilamellar bodies in the blood neutrophils of amiodarone‐treated patients may help to distinguish those patients at risk of long‐term amiodarone toxicity.